Spontaneous Smoking Cessation Before Lung Cancer Diagnosis

Slides:

Advertisements

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB Martin J. Edelman, MD, Lydia.

Advertisements

A Hole in the Heart Journal of Thoracic Oncology

Su K. Metcalfe, MD, MPH, Michael T

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients Björn.

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Electronic Updates for JTO Readers

Survival after resection of synchronous non–small cell lung cancer

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

A Hole in the Heart Journal of Thoracic Oncology

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

Prolonged Survival in Patients with Lung Cancer with Diabetes Mellitus

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Tasisulam Sodium (LY Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-II Study Giorgio.

Is the B12/CRP Index More Accurate Than You at Predicting Life Expectancy in Advanced Cancer Patients? Filipa Tavares, MD Journal of Pain and Symptom.

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer? Esther Dajczman, RN, MScA, Goulnar Kasymjanova, MD, PhD,

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Clinical Relevance of Our Multimodality Prognostic Score

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

It’s All in the “Swerve of the Curve”

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Pulmonary Resection for Metastases from Colorectal Cancer

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Ethnic Differences in the Management of Lung Cancer in New Zealand

Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

European Lung Cancer Conference (ELCC) 2016 Organisation

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer: A SEER Database Analysis Attila Dubecz, MD, Isabell Gall, MD, Norbert Solymosi,

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Spontaneous Smoking Cessation Before Lung Cancer Diagnosis Barbara G. Campling, MD, Bradley N. Collins, PhD, Kenneth M. Algazy, MD, Robert A. Schnoll, PhD, Miu Lam, PhD Journal of Thoracic Oncology Volume 6, Issue 3, Pages 517-524 (March 2011) DOI: 10.1097/JTO.0b013e318208c7da Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Kaplan-Meier distribution of intervals from cessation to diagnosis for lung cancer, myocardial infarction (MI), and prostate cancer. The difference between the groups was highly significant (p < 0.0001). Journal of Thoracic Oncology 2011 6, 517-524DOI: (10.1097/JTO.0b013e318208c7da) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Comparison of intervals from symptoms to diagnosis and from cessation to diagnosis for patients with lung cancer. Survival curves were generated using the Kaplan-Meier method. The probability of having stopped smoking is shown on the left y axis and the probability of having symptoms is shown on the right y axis. Those patients who were symptomatic at quitting are identified with arrows. Journal of Thoracic Oncology 2011 6, 517-524DOI: (10.1097/JTO.0b013e318208c7da) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier distribution of intervals from cessation to diagnosis for patients with lung cancer from the Veterans Affairs (VA) and the Kingston Regional Cancer Centre (KRCC). There was no significant difference between the two groups (p = 0.64). Journal of Thoracic Oncology 2011 6, 517-524DOI: (10.1097/JTO.0b013e318208c7da) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions